Double-Blind Clinical Trial for Evaluating the Effectiveness and Tolerability of Ageratina pichinchensis Extract on Patients with Mild to Moderate Onychomycosis. A Comparative Study with Ciclopirox

Abstract

Aerial parts of Ageratina pichinchensis have been used, in Mexican traditional medicine, as a remedy for the treatment of skin mycosis. Onychomycosis, also known as tinea of the nails or tinea unguium, constitutes an infection of the nails produced by dermatophytes. Clinically, onychomycosis is manifested by changes on the color, texture and thickness of the nail. The agent most frequently found in this disease is Tricophyton rubrum. The present study evaluated the therapeutic effectiveness and tolerability of topical administration of A. pichinchensis extract on the nails of patients with the clinical and mycological diagnosis of onychomycosis. A phytopharmaceutical formulation was developed in a lacquer solution containing the standardized (encecalin) extract of A. pichinchensis. A similar lacquer solution containing 8 % ciclopirox was used as control. Treatments were assigned randomly and administered topically for 6 months. Ninety six patients concluded the study (49 in the experimental group and 47 in the control); 71.1 % of patients from the experimental and 80.9 % from the control group showed therapeutic effectiveness, while 59.1 % and 63.8 % from the experimental and control group, respectively, achieved mycological effectiveness. Therapeutic success was observed in 55.1 and 63.8 %, respectively. No patient exhibited intense side effects. Statistical analysis demonstrated no differences between treatments.

Key words

Ageratina pichinchensis - Asteraceae - Onychomycosis - topic lacquer solution - dermatomycosis - encecalin

References

• 1 Rzedowski J, De Rzedowski G C. Flora fanerogámica del valle de México, 1st edition. México; Instituto de Ecología: Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional 1985: 454
• 2 Argueta A, Cano L, Rodarte M. Atlas de la medicina tradicional Mexicana. Tomos 1–3. México, D.F; Instituto Nacional Indigenista 1994: 1786
• 3 Avilés M, Suárez G. Catálogo de plantas medicinales jardín etnobotánico. México; Cuernavaca, Morelos, : Centro INAH 1994: 47
• 4 Monroy-Ortiz C, Castillo-España P. Plantas medicinales utilizadas en Morelos. México; Centro de Investigaciones Biológicas Universidad Autónoma del Estado de Morelos 2000: 61-2
• 5 Gómez F, Quijano L, Calderón J S, Perales A, Ríos T. 2, 2-Dimethylcromenes from Eupatorium aschembornianum.  Phytochemistry. 1982;  21 2095-7
• 6 Navarro V M, García A, González M, Fuentes A, Avilés M, Ríos Y. et al . Antifungal activities of nine traditional Mexican medicinal plants.  J Ethnopharmacol. 2003;  87 85-8
• 7 Ríos M Y, Aguilar-Guadarrama B, Navarro V M. Two new benzofuranes from Eupatorium aschenbornianum and their antimicrobial activity.  Planta Med. 2003;  69 967-70
• 8 Castañeda P, Gómez L, Mata R. Phytogrowth-inhibitory and antifungal constituents of Helianthella quinquenervis.  J Nat Prod. 1996;  59 323-6
• 9 Romero-Cerecero O, Rojas G, Navarro V, Herrera-Arellano H, Zamilpa-Álvarez A, Tortoriello J. Effectiveness and tolerability of a standardized extract from Ageratina pichinchensis on patients with tinea pedis. A double blind clinical trial.  Planta Med. 2006;  72 1257-61
• 10 Gupta A K, Joseph W S. Ciclopirox 8 % nail lacquer in the treatment of onychomycosis of the toenail in the United States.  J Am Podiat Med Assoc. 2000;  90 495-501
• 11 Ratnavel R C, Squire R A, Boorman G C. Clinical efficacies of shampoos containing ciclopirox olamine (1.5 %) and ketoconazole (2.0 %) in the treatment of seborrhoeic dermatitis.  J Dermatolog Treat. 2007;  18 88-96
• 12 Brenner M A, Harkless L B, Mendicino R W, Page J C. Ciclopirox 8 % nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.  J Am Podiat Med Assoc. 2007;  97 195-202
• 13 Gupta A K, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8 % in the treatment of toenail onychomycosis.  J Am Acad Dermatol. 2000;  43 S70-S80
• 14 Sidou F, Soto P. A randomized comparison of nail surface remanence of three nail lacquers, containing amorfiline 5 %, ciclopirox 8 % or triconazole 28 %, in healthy volunteers.  Int J Tissue React. 2004;  26 17-24
• 15 Arenas R. Dermatophytoses in Mexico.  Rev Iberoam Micol. 2002;  19 63-7
• 16 Madhuri J T, Raghu R R, Joga L D, Ratna K G. Onychomycosis: a significant medical problem.  Indian J Dermatol. 2002;  68 326-9
• 17 Campbell A W, Anyanwu E C, Morad M. Evaluation of the drug treatment and persistence of onychomycosis.  Sci World J. 2004;  4 60-77
• 18 Cedeño L, Vázquez del Mercado E, Arenas R. Onicomicosis en pacientes geriátricos. Dermatología cosmética, médica y quirúrgica. Available at http://dcmq.com.mx Accessed 2005.
• 19 Finch J J, Warshaw E M. Toenail onychomycosis: current and future treatment options.  Dermatol Ther. 2007;  20 31-46
• 20 Albert S F, Weis Z H. Management of onychomycosis with topicals.  Clin Podiat Med Surg. 2004;  21 605-15
• 21 Shemer A, Trau H, Davidovici B, Grunwald M H, Amichai B. Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail.  Dtsch Dermatol Ges. 2007;  5 1108-11
• 22 Einarson T R, Gupta A K, Shear N H, Arikan S. Clinical and economic factors in the treatment of onychomycosis.  Pharmacoeconomics. 1996;  9 307-20
• 23 Llambrich A, Lecha M. Tratamiento actual de la onicomicosis.  Rev Iberoam Micol. 2002;  19 127-9
• 24 Gupta A K, Lynde C W, Barber K. Pharmacoeconomic assessment of ciclopirox topical solution, 8 %, oral terbinafine, and oral itraconazole for onychomycosis.  J Cutan Med Surg. 2006;  10 ( 2) S54-62
• 25 Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.  Dermatol Treat. 2005;  16 327-30
• 26 Baran R, Gupta A K, Pierard G E. Pharmacotherapy of onychomycosis.  Expert Opin Pharmacother. 2005;  6 609-24